15110 DALLAS PKWY, SUITE 600, DALLAS, TX
Mangoceuticals, Inc. Enters Subscription Agreement for $272,000
Reg. FD
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
Mangoceuticals, Inc. Enters $75,000 Promissory Note with Tiger Cub Trust
Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Amended Quarterly Report
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence